Bioinformatics Analysis of Genes Upregulating Poor Prognosis In Colorectal Cancer And Gastric Cancer

Ruizhi Dong  
Jilin University First Hospital

Shaodong Li  
Jilin University First Hospital

Bin Liang  
Jilin University First Hospital

Zhenhua Kang (✉ 1269232708@qq.com)  
Jilin University First Hospital  https://orcid.org/0000-0001-6045-9663

Research Article

Keywords: colorectal cancer, gastric cancer, Poor prognosis, up-regulated gene, bioinformatics

DOI: https://doi.org/10.21203/rs.3.rs-635223/v1

License: ©️ This work is licensed under a Creative Commons Attribution 4.0 International License.  
Read Full License
Bioinformatics analysis of genes upregulating poor prognosis in colorectal cancer and gastric cancer

Ruizhi Dong, Shaodong Li, Bin Liang, Zhenhua Kang*
Department of Gastrointestinal Surgery, First Hospital of Jilin University, Changchun, Jilin Province 130000, People’s Republic of China

【Abstract】Purpose: To analyze the up-regulated genes of poor prognosis in colorectal cancer and gastric cancer by bioinformatics. Methods: We searched the gene expression profiles GSE156355 and GSE64916 in colorectal cancer and gastric cancer tissues in NCBI-GEO. With P value < 0.05 and log2>1 as the standard, Venn diagram software was used to identify the common DEGs in the two data sets. Kaplan Meier plotter was used to analyze the survival rate data of common differentially expressed genes, draw and select survival curves, and analyze their expression levels. Results: A total of 97 genes were detected to be up-regulated in the two gene expression profiles. There were 19 genes in the prognosis of gastric cancer and 15 genes in the prognosis of colorectal cancer that had significant differences in the survival rate. Among them, KCNQ1, TRIM29, GART, MSX1, SNAI1, SUV39H2, LOXL2 and KCTD14 significantly decreased the survival rate of gastric cancer and colorectal cancer. The expression of MSX1 was the highest in gastric cancer. The expression level of KCTD14 was the highest in colorectal cancer. The expression of MSX1 was the highest in gastric cancer. The expression of KCTD14 was the highest in colorectal cancer. Conclusion: There are 19 and 15 genes with significantly different prognostic viability in gastric cancer and colorectal cancer, respectively. The survival rates of KCNQ1, TRIM29, GART, Msx1, SNAI1, SUV39H2, LOXL2 and KCTD14 were significantly decreased in gastric cancer and colorectal cancer. The expression of MSX1 was the highest in gastric cancer. The expression of KCTD14 was the highest in colorectal cancer.

【Key words】colorectal cancer gastric cancer Poor prognosis up-regulated gene bioinformatics

Funding: No funding was received to assist with the preparation of this manuscript.
Conflicts of interest: The authors have no relevant financial or non-financial interests to disclose.
Availability of data and material: All data generated or analysed during this study are included in this published article [and its supplementary information files.
Code availability: Not applicable.
Authors' contributions: All authors contributed to the study conception and design. Material preparation, data collection and analysis were performed by [Ruizhi Dong], [Shaodong Li], [Bin Liang] and [Zhenhua Kang]. The first draft of the manuscript was written by [Ruizhi Dong], proofreading and reviewing was finished by [Zhenhua Kang] and all authors commented on previous versions of the manuscript. All authors read and approved the final manuscript.
Ethics approval: Not applicable.
Consent to participate: Not applicable.
Consent for publication: Consent for publication: Not applicable.

1 Materials and methods
1.1 Microarray data information

NCBI-GEO is seen as a microarray/gene map, and we got a gene microarray gene map. We search the NCBI-GEO (https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi) obtained in the tissue of colorectal cancer and stomach cancer gene expression profile GSE156355 and GSE64916. Gene expression profile GSE156355 was based on GPL21185 sequencing platform. Genome-wide microarray technology was used to compare the gene expression profiles of 6 colorectal cancer patients and 6 normal colorectal cancer tissues. Gene expression profile GSE64916 is based on the GPL13497 sequencing platform and uses the whole-genome and transcriptome analysis techniques to reveal the pathogenesis of peritoneal metastasis in advanced gastric cancer.

1.2 Screening of up-regulated differentially expressed genes (DEGs)

The screening of DEGS was identified by GEO2R online tool, and FDR (false discovery rate), which was corrected by P value, was the key index for differential gene screening. In the screening, P value < 0.05 and log2>1 were selected as the criteria (Fold Change represents the difference multiple) to screen out the up-regulated DEGS. Raw data in TXT format in the Venn software (online: http://bioinformatics.psb.ugent.be/webtools/Venn/) online check colorectal cancer and stomach cancer common DEGs two data set.

1.3 Gene ontology and pathway enrichment analysis

Gene ontology (GO) is a commonly used method to define genes and their RNA or protein products to identify unique biological characteristics of high-throughput transcriptome or genomic data. KEGG is a database covering genomes, diseases, biological pathways, drugs, and chemical materials. David was used to enrich BP, MF, CC and pathway of the screened up-regulated DEGs.

1.4 Survival analysis of core genes

Kaplan-Meier plotter [1] is a commonly used website tool, which is used to evaluate the effect of a large number of genes on survival based on EGA, TCGA database and GEO (Affymetrix microarray only), and to plot the survival curve of genes with common differential up-regulated expression in gastric cancer and colorectal cancer. Differential expression levels of genes that were significantly different in survival analysis between gastric cancer and colorectal cancer were analyzed.

2 Results

2.1 Identification of differentially up-regulated genes (DEGs) in colorectal cancer and gastric cancer

Through GEO2R online tool, the data of gene expression profiles GSE156355 and GSE64916 were extracted. With P value < 0.05 and log2>1 as the standard, the common DEGs in the two data sets were identified by Venn diagram software. A total of 2,494 and 805 DEGs were extracted from two datasets, GSE156355 and GSE64916, and the results showed that a total of 97 genes were detected to be up-regulated in the two gene expression profiles (Figure 1 and Table 1), which were the focus of this study.

Figure 1
Fig1 Validates the common DEGs in two data sets (GSE156355 and GSE64916) using the Venn Diagrams software
Note: Different colors mean different data sets

Table 1 Total up-regulated differentially expressed genes (DEGs)

| Names of differentially up-regulated genes |
|--------------------------------------------|
| KRT17, HILPDA, SERPINE2, SMIM13, REG3A, LOXL2, LAPT4M4B, MTAP, HOXA9, FERMT1, TSPAN6, ERLIN2, UBD, TMPRSS3, POLR1C, THOC3, DNAH14, LZTFL1, PRMT5, IFITM3, C8orf33, FAM64A, SLC39A10, PRAME, PMEPA1, GNPDA1, CA9, TGM2, ZNRF3, NAV2, SP5, KCTD14, FADS3, IGF2BP3, KCNQ1, EPHX4, MMP11, MYEOV, TLCD1, LRRC8E, GPR56, KLHL35, CCND1, GART, MSX1, ZNF239, LRP11, ASIC1, KIAA0895, PACSIN3, PROSER2, SLC3A2, TRPM2, KRT80, PFAS, FTSJ2, LRRC34, TMEM139, SLC4A11, E2F6, ZFP69B, YARS, HNRNPA2B1, LPCAT2, ATR, SUV39H2, CCNO, CXADR, TRIM29, CDK8, NOP56, POU5F1, QPCT, TMEM245, ZP3, ARHGEF39, TNFRSF12A, IFITM2, STC1, FAM57A, SIX1, ZNF174, SUV39H1, AGMAT, C10orf35, SLMO1, SNAI1, S100A3, HTR1D, CELSR1, MED12 |

2.2 Gene ontology and pathway enrichment analysis of up-regulated differentially expressed genes in gastric cancer and colorectal cancer

The results of GO analysis showed that for biological processes (BP), the up-regulated DEGs were rich in negative regulation of RNA polymerase II promoter transcription, drug response, negative regulation of DNA templated transcription, cell cycle, etc. For molecular function (MF), up-regulated DEGs are rich in protein binding, protein dimerization activity, transcription cosuppressor activity, etc.
For cell components (CC) upregulated DEGs are rich in nucleoplasm, membrane components, cytoplasm, etc. (Table 2).

KEGG analysis results were shown in Table 3, indicating that up-regulated DEGs were enriched into the HSA00230 pathway of purine metabolism, including POLR1c, GART, and PFas genes.

Table 2 Gene ontology analysis of common up-regulated differentially expressed genes (DEGs) in colorectal cancer and gastric cancer

| Category          | Term                                      | Count | p-Value  | FDR    |
|-------------------|-------------------------------------------|-------|----------|--------|
| GOTERM_BP_DIRECT  | GO:0000122–negative regulation of transcription from RNA polymerase II promoter | 11    | 0.001065 | 0.667791 |
|                   | GO:0035725–sodium ion transmembrane transport | 4     | 0.003942 | 1.000000 |
|                   | GO:0034341–response to interferon-gamma | 3     | 0.004836 | 1.000000 |
|                   | GO:0042493–response to drug | 6     | 0.010374 | 1.000000 |
|                   | GO:0036123–histone H3-K9 dimethylation | 2     | 0.012986 | 1.000000 |
|                   | GO:0007049–cell cycle | 5     | 0.014749 | 1.000000 |
|                   | GO:0007605–sensory perception of sound | 4     | 0.020199 | 1.000000 |
|                   | GO:0030178–negative regulation of Wnt signaling pathway | 3     | 0.021487 | 1.000000 |
|                   | GO:0036124–histone H3-K9 trimethylation | 2     | 0.021550 | 1.000000 |
|                   | GO:0060536–cartilage morphogenesis | 2     | 0.0258058 | 1.000000 |
|                   | GO:0006189–‘de novo’ IMP biosynthetic process | 2     | 0.0258058 | 1.000000 |
|                   | GO:0042754–negative regulation of circadian rhythm | 2     | 0.0384612 | 1.000000 |
GO:0035456~response to interferon-beta
  2 0.0384612

GO:0035455~response to interferon-alpha
  2 0.0426436

GO:0044070~regulation of anion transport
  2 0.0426436

GO:0042118~endothelial cell activation
  2 0.0426436

GO:0009952~anterior/posterior pattern specification
  3 0.047390

GO:0060070~canonical Wnt signaling pathway
  3 0.050615

GO:0043517~positive regulation of DNA damage response, signal transduction by p53 class mediator
  2 0.0509545

GO:0051926~negative regulation of calcium ion transport
  2 0.055083

GO:0009168~purine ribonucleoside monophosphate biosynthetic process
  2 0.055083

GO:0003198~epithelial to mesenchymal transition involved in endocardial cushion formation
  2 0.055083

GO:0009607~response to biotic stimulus
  2 0.059194

GO:0060071~Wnt signaling pathway, planar cell polarity
  3 0.060741
| GO Term                                      | Count | P-value | Adjusted P-value |
|---------------------------------------------|-------|---------|------------------|
| GO:0071456--cellular response to hypoxia     | 3     | 0.065447| 1                |
| GO:0045892--negative regulation of transcription, DNA-templated | 6     | 0.065880| 1                |
| GO:0090280--positive regulation of calcium ion import | 2     | 0.067363| 1                |
| GO:0036342--post-anal tail morphogenesis    | 2     | 0.075462| 1                |
| GO:0046597--negative regulation of viral entry into host cell | 2     | 0.075462| 1                |
| GO:0042474--middle ear morphogenesis        | 2     | 0.083492| 1                |
| GO:0070588--calcium ion transmembrane transport | 3     | 0.094641| 1                |
| GOTERM_MF_DIRECT                            |       |         |                  |
| GO:0005272--sodium channel activity         | 3     | 0.002183| 0.236464         |
| GO:0005515--protein binding                 | 55    | 0.002341| 0.236464         |
| GO:0046974--histone methyltransferase activity (H3-K9 specific) | 2     | 0.023184| 1                |
| GO:0000976--transcription regulatory region sequence-specific DNA binding | 3     | 0.030189| 1                |
| GO:0046983--protein dimerization activity   | 4     | 0.033305| 1                |
| GO:0003714--transcription corepressor activity | 4     | 0.069793| 1                |
| GO:0035198--miRNA binding                   | 2     | 0.072337| 1                |
| GOTERM_CC_DIRECT                            |       |         |                  |
| GO:0005654--nucleoplasm                     | 22    | 0.00764 | 0.502637         |
Table 3 KEGG Pathway analysis of differentially up-regulated genes in colorectal cancer and gastric cancer

| Pathway ID | Name                  | Count | Genes                     | PValue  |
|------------|-----------------------|-------|---------------------------|---------|
| hsa00230   | Purine metabolism     | 3     | POLR1C, GART, PFAS        | 0.054942|

### 2.2 Survival analysis of core genes

Kaplan Meier plotter (http://kmplot.com/analysis) for a total of differentially expressed genes of survival data statistics, drawing and survival curve (P < 0.05). The results showed that there were 19 genes with significant differences in survival rate in gastric cancer patients (Figure 2). There were 15 genes in prognostic colorectal cancer (Figure 3) that differed significantly in patient survival; Among them, KCNQ1, TRIM29, GART, MSX1, SNAI1, SUV39H2, LOXL2 and KCTD14 (Table 4) were significantly reduced in prognosis analysis of gastric cancer and colorectal cancer. The expression level analysis (Figure 4) showed that the expression level of Msx1 was the highest in gastric cancer. The expression of KCTD14 was the highest in colorectal cancer, and there was no significant difference in the expression of other genes.
Fig. 2 Prognostic information of core genes in gastric cancer. The survival rate of 19 genes was significantly decreased (P<0.05) when Kaplan-Meier plotter was used to identify the prognosis of patients.

Figure 3
Fig. 3 Prognostic information of core genes in colorectal cancer. Using Kaplan-Meier plotter online tool to identify patients' prognosis information, the survival rate of 15 genes was significantly decreased (P<0.05).

Table 4 Genes differentially expressed in survival analysis of gastric cancer and colorectal cancer

| type               | The name of the gene                  |
|--------------------|--------------------------------------|
| Cancer of the stomach | CDK8  KCNQ1  TRIM29  GART  MSX1  HILPDA  NOP56  POLP1C  SNAI1  SUV39H2  SUV39H1  SLC3A2  CCNO  YARS  PFAS  LOXL2  CCND1  KCTD14  TGM2 |
| Colorectal cancer | KCNQ1  POU5F1  TRIM29  IFITM2  GART  MSX1  NAV2  FAM57A  SNAI1  SUV39H2  GNPDA1  ATR  PFAS  LOXL2  KCTD14 |

3 Discuss

Gastric cancer and colorectal cancer are malignant gastrointestinal tumors with high morbidity and mortality in the world. The prognosis of patients with colorectal cancer and gastric cancer has a serious impact on the quality of life of patients. The occurrence of digestive tract tumors is closely
related to gene regulation, environmental factors and dietary habits. At present, it is believed at home and abroad that gene regulation is still the main factor of the disease, and the prognosis of gastric cancer and colorectal cancer is also closely related to many genes [2-4].

In order to identify the expression of more differential genes in digestive tract tumors, gene profiles GSE156355 and GSE64916 were screened in the NCBI-GEO microarray database. A total of 97 genes were detected to be up-regulated in the two gene expression profiles with P value < 0.05 and log2>1 as the standard. Kaplan Meier plotter was used to analyze the survival rate data of shared differentially expressed genes, and survival curves were drawn and selected (P<0.05). The results showed that there were 19 genes with significant difference in survival rate in patients with gastric cancer. In colorectal cancer, there were 15 genes with significant differences in patient survival; Among them, 8 genes, KCNQ1, TRIM29, GART, MSX1, SNAI1, SUV39H2, LOXL2 and KCTD14, were significantly reduced in prognosis and survival rate in gastric cancer and colorectal cancer. The expression level of MSX1 was the highest in gastric cancer. The expression of KCTD14 was the highest in colorectal cancer, and there was no significant difference in the expression of other genes.

Studies have found that gastric cancer is the second largest cause of cancer death in the world, and it is a common malignant tumor in China. How to achieve early diagnosis and early surgery is an important factor to determine the prognosis of patients. For patients in advanced stage, postoperative recurrence and drug resistance, the effect of radiotherapy and chemotherapy is poor and the toxic side effects are large, and effective treatment is lacking. Therefore, it is urgent to find specific molecular markers for early cancer diagnosis and effective treatment with low toxicity [5, 6]. Luo L[7] found that there is hypermethylation and silencing of the promoter CpG island of several tumor suppressor genes in gastric cancer, including the Wnt antagonist DKK3 and the newly discovered candidate gene Msx1 gene, which can be up-regulated after demethylation, indicating that it is an ideal target for tumor treatment. As a newly emerged Msx1 gene, the expression difference of Msx1 in precancerous lesions and gastric cancer tissues can be further understood in large clinical samples, and whether it is an early tumor molecular marker can be studied. And further study its function as a tumor suppressor gene and its mechanism. Bioinformatics analysis in this study also confirmed this point, and MSX1 gene is closely related to the occurrence of gastric cancer, which can be used as an important indicator of detection and an effective target in the diagnosis and treatment of gastric cancer.

Studies have shown that the low expression of the homologous gene KCTD11 of KCTD14 is associated with poor prognosis. The overexpression of KCTD11 inhibits the proliferation and migration of lung cancer cells, and the results are reversed after knockout[8, 9]. Tong Rongliang[10, 11] also found low expression of KCTD11 in the tissues of patients with hepatocellular carcinoma. Heterozygosity loss is one of the causes of low expression of KCTD11, and low expression of KCTD11 suggests poor long-term prognosis. Natural killer cells (NK cells) are effector cells of the natural immune system, which play an important role in resisting pathogen invasion and anti-tumor, and the negative regulation of KCTD9 molecule plays an important role in the proliferation of NK cells[12-14]. Li Yu[15], Zhou Xiaolong[16] and Liu Zhuoqing[17] demonstrated the relationship between KCTD14 gene and the migration and invasion of breast cancer cells, cell proliferation and its expression differences as well as its clinicopathological significance. In this study, it was found that the expression of KCTD14 was the highest in colorectal cancer. KCTD14 gene is closely related to the occurrence of colorectal cancer, and can be used as an important indicator for detection and an effective target for diagnosis and treatment of colorectal cancer.
Reference

[1] Marcell S A, András L, Ádám N, et al. Cross-validation of survival associated biomarkers in gastric cancer using transcriptomic data of 1,065 patients[J]. Oncotarget, 2016,7(31).

[2] Guilford P J, Holyoake A J. Markers for detection of gastric cancer[J]. 2007.

[3] Shiotani A, Iishi H, Uedo N, et al. Histologic and serum risk markers for noncardia early gastric cancer.[J]. International Journal of Cancer, 2005,115(3):463-469.

[4] Duffy M J, Lamerz R, Haglund C, et al. Tumor markers in colorectal cancer, gastric cancer and gastrointestinal stromal cancers: European group on tumor markers 2014 guidelines update[J]. International Journal of Cancer, 2014,134(11):2513-2522.

[5] Zha Zhenqiu, Liu Zhirong, Zheng Rongshou, et al.Analysis of the incidence and death of brain and nervous system tumors in tumor registries in China from 2008 to 2012 [J]. Chinese Journal of Disease Control, 2018,22(11):19-23.

[6] Chen Wanqing, Zhang Siwei, Zheng Rongshou, et al. Analysis of cancer incidence and death in China in 2007[J]. China tumor, 2011(03):5-12.

[7] Luo Lin.Effect of quercetin on the reversal of promoter methylation of Msx1 and DKK3 in gastric cancer and its mechanism .Chongqing Medical University, 2011.

[8] Yang Man. KCTD11 regulates the activity of Wnt pathway and Hippo pathway through binding with β-catenin - inhibiting the proliferation and metastasis of lung cancer cells[J].China Medical University, 2020.

[9] Mancarelli M M, Zazzeroni F, Ciccocioppo L, et al. The tumor suppressor gene KCTD11RENa is regulated by Sp1 and methylation and its expression is reduced in tumors[J]. Molecular Cancer, 2010,9(1):172.

[10] Tong RongliangExpression and mechanism of KCTD11 in hepatocellular carcinoma.[D]. Zhejiang University, 2018.

[11] Tong R, Yang B, Xiao H, et al. KCTD11 inhibits growth and metastasis of hepatocellular carcinoma through activating Hippo signaling[J]. Oncotarget, 2017,8(23).

[12] Zhang Xiaoping. The role of KCTD9 molecule in the development and function of NK cells[D].Huazhong University of Science and Technology , 2019.

[13] Chen T, Zhu L, Zhou Y, et al. KCTD9 contributes to liver injury through NK cell activation during hepatitis B virus-induced acute-on-chronic liver failure.[J]. Clinical Immunology, 2013,146(3):207-216.

[14] Chen, T., Zhu, et al. KCTD9 contributes to liver injury through NK cell activation during hepatitis B virus-induced acute-on-chronic liver failure[J]. CLINICAL IMMUNOLOGY -SAN DIEGO-ACADEMIC PRESS-, 2013.

[15] Li Yu.Effects of silencing of CPNE1, KCTD14 and FundC2 genes on migration and invasion of MDA-MB-231 cells [J]. University of South China, 2019.

[16] Zhou Xiaolong.Effects of silencing of CPNE1, FundC2, KCTD14 and Vimentin on proliferation of MDA-MB-231 cells [J].University of south China , 2019.

[17] Liu Zhaoqing. Expression differences of CPNE1, KCTD14 and FundC2 in Luminal subtype and triple negative breast cancer and their clinicopathological significance[J]. University of South China, 2019.